SLDB missed EPS expectations by 21.61%
Mar 13, 2025, 10:34 PM
0.00%
What does SLDB do
Solid Biosciences, headquartered in Charlestown, Massachusetts, develops gene therapies for Duchenne muscular dystrophy and other cardiac diseases, employing 88 staff since its IPO on January 26, 2018. Their pipeline includes multiple gene therapy candidates and novel platform technologies.
Solid Biosciences (SLDB) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Solid Biosciences's actual EPS was -$1.00, missing the estimate of -$0.82 per share, resulting in a -21.61% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.